United States Biotechnology & Medical Research

Ovid Therapeutics Inc (OVID)

Track

Ovid Therapeutics Inc. recorded one notable insider transaction recently, involving a proposed sale of 150,000 shares valued at $420,000 by an affiliated stockholder on August 14, 2026. This activity follows a positive earnings report where the company beat expectations by 40%, occurring amidst a 17.4% stock price increase over the past quarter.
Ticker: OVID Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Ovid Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
Jeffrey A. Rona Affiliated Stockholder Large shareholder
Transaction date
Proposed sale
Price
187.53
Quantity 32,342
Value US$4,709,821
3.3
Rona Jeffrey A CBFO Officer
Transaction date
Planned sale
Price
362.62
Quantity 15,708 -26.8%
Value US$4,361,498
1.8
ALEXANDER MARGARET A. President and CEO Executive Director
Transaction date
Sale
Price
436.01
Quantity 69,873 -44.4%
Value US$3,561,516
1.8
ALEXANDER MARGARET A. President and COO Officer
Transaction date
Sale
Price
0.56
Quantity 5,279 -6.7%
Value US$2,956
3.3
Rona Jeffrey A CBFO Officer
Transaction date
Sale
Price
0.56
Quantity 3,902 -5.4%
Value US$2,185
1.8
ALEXANDER MARGARET A. President and COO Officer
Transaction date
Purchase
Price
0.73
Quantity 6,810 +24.2%
Value US$4,971
3.0
LEVIN JEREMY M CEO Executive Director
Transaction date
Purchase
Price
2.76
Quantity 18,248 +0.5%
Value US$50,364
2.2
Tardio Jason Chief Operating Officer Officer
Transaction date
Planned sale
Price
2.15
Quantity 17,344 -100.0%
Value US$37,290
3.0
LEVIN JEREMY M CEO Executive Director Large shareholder
Transaction date
Purchase
Price
5.84
Quantity 8,488 +0.1%
Value US$49,570
TAKEDA PHARMACEUTICAL CO LTD Large shareholder
Transaction date
Purchase
Price
2.50
Quantity 2,000,000 +53.3%
Value US$5,000,000
3.0
LEVIN JEREMY M CEO Executive Director Large shareholder
Transaction date
Purchase
Price
2.50
Quantity 60,000 +1.3%
Value US$150,000
0.7
Bernstein Karen Non-Executive Director
Transaction date
Purchase
Price
2.02
Quantity 10,000 +100.0%
Value US$20,210
3.0
LEVIN JEREMY M CEO Executive Director Large shareholder
Transaction date
Purchase
Price
2.00
Quantity 75,000 +1.6%
Value US$150,000
Bernstein Karen Non-Executive Director
Transaction date
Purchase
Price
6.23
Quantity 10,000 +inf%
Value US$62,300
WILLIAMS DOUGLAS E Non-Executive Director
Transaction date
Purchase
Price
6.49
Quantity 5,000 +inf%
Value US$32,442
LEVIN JEREMY M CEO Executive Director Large shareholder
Transaction date
Purchase
Price
7.15
Quantity 15,334 +0.3%
Value US$109,638
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-14 2026-08-14 PrS Proposed sale
3.3
Jeffrey A. Rona

Affiliated Stockholder

Large shareholder
32,342
187.53
US$4,709,821 		32,342 187.53 US$4,709,821
2026-03-02 2026-02-23 PlS Planned sale
3.3
Rona Jeffrey A

CBFO

Officer
15,708 -26.8%
362.62
US$4,361,498 		15,708 -26.8% 362.62 US$4,361,498
2026-03-02 2026-02-23 S Sale
1.8
ALEXANDER MARGARET A.

President and CEO

Executive Director
69,873 -44.4%
436.01
US$3,561,516 		69,873 -44.4% 436.01 US$3,561,516
2025-02-28 2025-02-26 S Sale
1.8
ALEXANDER MARGARET A.

President and COO

Officer
5,279 -6.7%
0.56
US$2,956 		5,279 -6.7% 0.56 US$2,956
2025-02-28 2025-02-26 S Sale
3.3
Rona Jeffrey A

CBFO

Officer
3,902 -5.4%
0.56
US$2,185 		3,902 -5.4% 0.56 US$2,185
2025-01-29 2025-01-27 B Purchase
1.8
ALEXANDER MARGARET A.

President and COO

Officer
6,810 +24.2%
0.73
US$4,971 		6,810 +24.2% 0.73 US$4,971
2024-03-20 2024-03-18 B Purchase
3.0
LEVIN JEREMY M

CEO

Executive Director
18,248 +0.5%
2.76
US$50,364 		18,248 +0.5% 2.76 US$50,364
2022-09-14 2022-09-12 PlS Planned sale
2.2
Tardio Jason

Chief Operating Officer

Officer
17,344 -100.0%
2.15
US$37,290 		17,344 -100.0% 2.15 US$37,290
2020-09-01 2020-08-28 B Purchase
3.0
LEVIN JEREMY M

CEO

Executive Director Large shareholder
8,488 +0.1%
5.84
US$49,570 		8,488 +0.1% 5.84 US$49,570
2019-11-22 2019-10-08 B Purchase TAKEDA PHARMACEUTICAL CO LTD Large shareholder
2,000,000 +53.3%
2.50
US$5,000,000 		2,000,000 +53.3% 2.50 US$5,000,000
2019-10-10 2019-10-08 B Purchase
3.0
LEVIN JEREMY M

CEO

Executive Director Large shareholder
60,000 +1.3%
2.50
US$150,000 		60,000 +1.3% 2.50 US$150,000
2019-02-28 2019-02-26 B Purchase
0.7
Bernstein Karen
Non-Executive Director
10,000 +100.0%
2.02
US$20,210 		10,000 +100.0% 2.02 US$20,210
2019-02-26 2019-02-22 B Purchase
3.0
LEVIN JEREMY M

CEO

Executive Director Large shareholder
75,000 +1.6%
2.00
US$150,000 		75,000 +1.6% 2.00 US$150,000
2018-08-16 2018-08-14 B Purchase Bernstein Karen Non-Executive Director
10,000 +inf%
6.23
US$62,300 		10,000 +inf% 6.23 US$62,300
2018-08-16 2018-08-14 B Purchase WILLIAMS DOUGLAS E Non-Executive Director
5,000 +inf%
6.49
US$32,442 		5,000 +inf% 6.49 US$32,442
2017-08-28 2017-08-25 B Purchase LEVIN JEREMY M

CEO

Executive Director Large shareholder
15,334 +0.3%
7.15
US$109,638 		15,334 +0.3% 7.15 US$109,638
Explore more

More insider trading research around Ovid Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America